{"id":"W2897890026","doi":"10.1016/s0140-6736(18)31946-9","title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","year":2018,"lang":"en","type":"article","venue":"The Lancet","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":359,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta","funders":"Janssen Biotech; Pfizer Pharmaceuticals; Chugai Pharmaceutical; Genentech; Eisai; Astellas Pharma; UCB; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Gilead Sciences; AbbVie; Sanofi; Novartis; GlaxoSmithKline; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ixekizumab; Medicine; Adalimumab; Placebo; Ankylosing spondylitis; Internal medicine; Axial spondyloarthritis; Spondylitis; Secukinumab; Physical therapy; Sacroiliitis; Disease; Psoriatic arthritis; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002659954,0.001477779,0.003560835,0.0004135981,0.0003848725,0.001145997,0.0009080786,0.002443953,0.003460209],"category_scores_gemma":[0.001821378,0.0007102479,0.003234341,0.0004662755,0.0012697,0.001009673,0.0003842284,0.002936558,0.0006647162],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006883686,"about_ca_system_score_gemma":0.001018901,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001623895,"about_ca_topic_score_gemma":0.003131293,"domain_scores_codex":[0.9992,0.0004342549,0.00007342505,0.0001144448,0.00005885118,0.0001190926],"domain_scores_gemma":[0.9989879,0.0003849577,0.0002264608,0.00008062505,0.00006645072,0.0002536435],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9797812,0.001813036,0.0006016993,0.001299474,0.00148219,0.00004664728,0.00006138052,0.0001847755,0.002330685,0.00006692175,0.0005467112,0.01178524],"study_design_scores_gemma":[0.9767593,0.02090831,0.001097627,0.0000426929,0.0005337345,0.00002766539,0.00001714647,0.00007709547,0.0001972013,0.00004607262,0.0002852616,0.000007779071],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9684103,0.02497302,0.0005264806,0.0009182513,0.0006746065,0.001620805,0.001127189,0.00009556903,0.001653892],"genre_scores_gemma":[0.9753125,0.01404611,0.00170466,0.001560787,0.0007066378,0.001573962,0.001467074,0.0000310201,0.003597327],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003560835,"threshold_uncertainty_score":0.01406729,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04721040121979949,"score_gpt":0.3179318293990595,"score_spread":0.27072142817926,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}